Dual-Functionalized Nanoliposomes Achieve a Synergistic Chemo-Phototherapeutic Effect

Abstract

The enhancement of photodynamic therapy (PDT) effectiveness by combining it with other treatment modalities and improved drug delivery has become an interesting field in cancer research. We have prepared and characterized nanoliposomes containing the chemotherapeutic drug irinotecan (CPT11lip), the photodynamic agent protoporphyrin IX (PpIXlip), or their combination (CPT11-PpIXlip). The effects of individual and bimodal (chemo-phototherapeutic) treatments on HeLa cells have been studied by a combination of biological and photophysical studies. Bimodal treatments show synergistic cytotoxic effects on HeLa cells at relatively low doses of PpIX/PDT and CPT11. Mechanistic cell inactivation studies revealed mitotic catastrophe, apoptosis, and senescence contributions. The enhanced anticancer activity is due to a sustained generation of reactive oxygen species, which increases the number of double-strand DNA breaks. Bimodal chemo-phototherapeutic liposomes may have a very promising future in oncological therapy, potentially allowing a reduction in the CPT11 concentration required to achieve a therapeutic effect and overcoming resistance to individual cancer treatments.

Special Issue “Application Progress of Liposomes in Drug Development”

“…The study by Lazaro-Carrillo et al [ 11 ] presents an innovative approach by coencapsulating the chemotherapeutic drug irinotecan and the photosensitizer protoporphyrin IX within liposomes for potential chemophototherapy. Through confocal microscopy, the colocalization of the two drugs in the cytoplasm and their partial colocalization at the plasma membrane were observed, suggesting potential synergistic interactions.…”